Vistagen公布Fasedienol治疗社交焦虑障碍Palisade-4三期临床研究开放标签扩展部分初步积极数据

美股速递
Sep 22

Vistagen今日宣布,其在研药物Fasedienol用于社交焦虑障碍急性治疗的关键性Palisade-4三期临床研究,其开放标签扩展部分已取得初步积极数据。

这一消息标志着该候选药物在解决社交焦虑这一重大未满足医疗需求方面又迈出了坚实一步。公司表示,来自扩展阶段的研究结果进一步佐证了Fasedienol在先前已报道的安慰剂对照部分所展现出的疗效与安全性特征。

Palisade-4研究是一项设计严谨、规模可观的三期临床试验,旨在全面评估Fasedienol在社交焦虑障碍患者急性症状管理中的潜力。而此次公布的开放标签扩展阶段数据,则为长期用药的安全性及耐受性提供了有价值的补充证据。Vistagen强调,这些发现将为其后续的监管注册申报及临床开发战略提供重要参考,有望为全球数以百万计的社交焦虑症患者带来新的治疗选择。公司计划在未来的医学会议或同行评审期刊上公布更详尽的分析结果。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10